Ultragenyx’s A number of Business Belongings And Candidates Impress Analyst; Sees Strong Upside – Ultragenyx Pharmaceutical (NASDAQ:RARE)

Along with the 2025 J.P. Morgan Healthcare Convention, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.

The analyst retains an Chubby ranking on Ultragenyx with a value goal of $102 and says the corporate is uniquely positioned in the long run with an expansive and various pipeline of orphan illness belongings and extremely regarded administration. JP Morgan sees a number of value-creating catalysts over the following six to 18 months.

• Ultragenyx’s latest assembly centered on setrusumab and the continuing Section 3 ORBIT trial. The analyst famous that the corporate stays assured within the trial’s success, with a second interim evaluation anticipated by mid-2025 and remaining outcomes by the top of 2025.
• At present share ranges, the analyst famous the market is just not absolutely valuing the setrusumab program and anticipates optimistic trial information may push Ultragenyx inventory value to a ~$7-handle.
• Ultragenyx emphasised that shifting ahead to the second interim evaluation doesn’t change the research’s chance of success. As a substitute, the extra time permits for clearer differentiation between the setrusumab and placebo teams, with the minimal follow-up rising from 7 months within the first interim evaluation to 12 months within the second.
• On the business entrance, Ultragenyx plans to leverage its current Crysvita infrastructure within the U.S. for setrusumab, given overlapping name factors.
• Approval may additionally make the corporate eligible for a Precedence Assessment Voucher, offering a possible supply of non-dilutive capital. In Europe, the place Mereo owns the rights, Ultragenyx will lead the regulatory submitting course of and anticipates submitting round 2-3 months after the U.S. submitting.

On Sunday, Ultragenyx reported preliminary 2024 income of $555 million—$560 million, in comparison with the consensus of $543.02 million.

Crysvita’s income for 2024 is estimated to be $405 million—$410 million, and Dojolvi’s income is estimated to be $87 million—$89 million.

The corporate expects 2025 gross sales of $640 million—$670 million versus a consensus of $648.54 million.

Worth Motion: RARE inventory is up 4.31% at $41.75 ultimately test Wednesday.

Learn Subsequent:

Photograph through Shutterstock.